Kukje Pharma Co., Ltd. (002720.KS)
KRW 4970.0
(-2.17%)
KRW 4970.0
(-2.17%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.03 Billion KRW | -79.42% |
| 2022 | 9.76 Billion KRW | 167.83% |
| 2021 | 4.07 Billion KRW | -57.69% |
| 2020 | 9.66 Billion KRW | 127.37% |
| 2019 | 8.81 Billion KRW | -45.22% |
| 2018 | 6.02 Billion KRW | 39.49% |
| 2017 | 5.2 Billion KRW | -7.82% |
| 2016 | 6.85 Billion KRW | 92.47% |
| 2015 | 3.24 Billion KRW | 830.8% |
| 2014 | -517.9 Million KRW | -107.0% |
| 2013 | 5.12 Billion KRW | 160.12% |
| 2012 | -10.03 Billion KRW | -256.87% |
| 2011 | 6.36 Billion KRW | -53.23% |
| 2010 | 13.66 Billion KRW | -16.59% |
| 2009 | 16.36 Billion KRW | -4.75% |
| 2008 | 15.91 Billion KRW | 9.49% |
| 2007 | 14.86 Billion KRW | -0.92% |
| 2006 | 15.84 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 4.21 Billion KRW | 1143.61% |
| 2024 Q2 | 1.49 Billion KRW | -56.12% |
| 2023 Q1 | 2.68 Billion KRW | 420.7% |
| 2023 Q4 | -472.29 Million KRW | -103.02% |
| 2023 FY | - KRW | -79.42% |
| 2023 Q3 | 15.63 Billion KRW | -14.16% |
| 2023 Q2 | 18.21 Billion KRW | 577.42% |
| 2022 FY | - KRW | 167.83% |
| 2022 Q1 | 4.42 Billion KRW | 262.36% |
| 2022 Q4 | 516.33 Million KRW | -80.45% |
| 2022 Q2 | 3.17 Billion KRW | -28.23% |
| 2022 Q3 | 2.64 Billion KRW | -16.88% |
| 2021 Q1 | 2.57 Billion KRW | 218.23% |
| 2021 Q2 | 1.57 Billion KRW | -38.78% |
| 2021 Q3 | 2.58 Billion KRW | 64.14% |
| 2021 Q4 | -2.72 Billion KRW | -205.29% |
| 2021 FY | - KRW | -57.69% |
| 2020 Q3 | 2.19 Billion KRW | 6.24% |
| 2020 Q2 | 2.06 Billion KRW | -72.4% |
| 2020 FY | - KRW | 127.37% |
| 2020 Q1 | 7.48 Billion KRW | 1769.6% |
| 2020 Q4 | -2.17 Billion KRW | -199.32% |
| 2019 Q3 | 2.33 Billion KRW | 207.93% |
| 2019 FY | - KRW | -45.22% |
| 2019 Q1 | 3.6 Billion KRW | 216.46% |
| 2019 Q2 | -2.16 Billion KRW | -160.08% |
| 2019 Q4 | 400.38 Million KRW | -82.87% |
| 2018 FY | - KRW | 39.49% |
| 2018 Q4 | 1.13 Billion KRW | -55.49% |
| 2018 Q3 | 2.55 Billion KRW | 38.52% |
| 2018 Q2 | 1.84 Billion KRW | -11.13% |
| 2018 Q1 | 2.07 Billion KRW | 209.38% |
| 2017 Q4 | 672 Million KRW | -64.5% |
| 2017 Q1 | 1.9 Billion KRW | 28.18% |
| 2017 FY | - KRW | -7.82% |
| 2017 Q2 | 1.62 Billion KRW | -14.79% |
| 2017 Q3 | 1.89 Billion KRW | 16.7% |
| 2016 Q4 | 1.48 Billion KRW | 37.05% |
| 2016 Q1 | 2.16 Billion KRW | 194.27% |
| 2016 Q2 | 1.19 Billion KRW | -45.02% |
| 2016 Q3 | 1.08 Billion KRW | -9.11% |
| 2016 FY | - KRW | 92.47% |
| 2015 Q3 | 390.31 Million KRW | -86.44% |
| 2015 Q4 | -2.3 Billion KRW | -689.46% |
| 2015 FY | - KRW | 830.8% |
| 2015 Q1 | 2.11 Billion KRW | 144.22% |
| 2015 Q2 | 2.87 Billion KRW | 36.1% |
| 2014 Q1 | 553.74 Million KRW | -77.62% |
| 2014 Q4 | -4.78 Billion KRW | -292.67% |
| 2014 Q3 | 2.48 Billion KRW | 87.4% |
| 2014 Q2 | 1.32 Billion KRW | 139.1% |
| 2014 FY | - KRW | -107.0% |
| 2013 Q1 | 1.65 Billion KRW | 133.33% |
| 2013 FY | - KRW | 160.12% |
| 2013 Q3 | 17.37 Million KRW | -99.07% |
| 2013 Q4 | 2.47 Billion KRW | 14141.55% |
| 2013 Q2 | 1.87 Billion KRW | 13.31% |
| 2012 Q4 | -4.96 Billion KRW | -1215.37% |
| 2012 FY | - KRW | -256.87% |
| 2012 Q2 | -5.03 Billion KRW | -256.49% |
| 2012 Q3 | 445.41 Million KRW | 108.84% |
| 2012 Q1 | -1.41 Billion KRW | 0.0% |
| 2011 Q3 | 1.84 Billion KRW | -10.12% |
| 2011 Q1 | 4.73 Billion KRW | 59.78% |
| 2011 Q2 | 2.05 Billion KRW | -56.67% |
| 2011 FY | - KRW | -53.23% |
| 2010 Q4 | 2.96 Billion KRW | -13.79% |
| 2010 FY | - KRW | -16.59% |
| 2010 Q1 | 2.85 Billion KRW | -46.23% |
| 2010 Q2 | 3.17 Billion KRW | 11.29% |
| 2010 Q3 | 3.43 Billion KRW | 8.14% |
| 2009 Q2 | 3.41 Billion KRW | 17.28% |
| 2009 Q3 | 4.67 Billion KRW | 36.89% |
| 2009 Q4 | 5.3 Billion KRW | 13.46% |
| 2009 FY | - KRW | -4.75% |
| 2009 Q1 | 2.91 Billion KRW | -48.93% |
| 2008 Q3 | 4.05 Billion KRW | -10.06% |
| 2008 FY | - KRW | 9.49% |
| 2008 Q2 | 4.51 Billion KRW | 22.36% |
| 2008 Q4 | 5.7 Billion KRW | 40.66% |
| 2008 Q1 | 3.68 Billion KRW | 4.81% |
| 2007 Q3 | 4.28 Billion KRW | 2.21% |
| 2007 FY | - KRW | -0.92% |
| 2007 Q2 | 4.19 Billion KRW | 0.0% |
| 2007 Q4 | 3.51 Billion KRW | -17.95% |
| 2006 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 121.336% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 100.733% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 98.381% |
| HANDOK Inc. | 35.06 Billion KRW | 102.956% |
| Yuhan Corporation | 127.43 Billion KRW | 100.813% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | 102.763% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 95.22% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 100.321% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | 120.772% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 106.856% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | 130.301% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | 122.901% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | 102.921% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 121.336% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | 94.388% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | 115.814% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 97.897% |
| JW Holdings Corporation | 187.88 Billion KRW | 100.552% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 97.977% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 100.365% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 101.162% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 97.203% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | 107.847% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | 108.764% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | 105.557% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 121.336% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | 101.886% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 100.629% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 101.162% |
| Yuhan Corporation | 127.43 Billion KRW | 100.813% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | 103.096% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | 113.55% |
| Suheung Co., Ltd. | 77.02 Billion KRW | 101.346% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 101.162% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | 102.83% |
| Korea United Pharm Inc. | 70.78 Billion KRW | 101.464% |
| CKD Bio Corp. | -1.63 Billion KRW | 36.424% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | 102.082% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | 103.183% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | 102.816% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 97.203% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | 101.664% |
| Boryung Corporation | 114.28 Billion KRW | 100.907% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 96.609% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 106.856% |
| JW Lifescience Corporation | 50.82 Billion KRW | 102.039% |